ClinicalTrials.gg
RecruitingNCT05165706Updated Dec 4, 2024

Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance

An interventional study of Dietary Intervention Mediterranean Low Carbohydrate Diet and Dietary Intervention Standard Low Carbohydrate Diet in Diabetes Mellitus, Type 2, PreDiabetes and Insulin Resistance, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Diabetes Mellitus, Type 2 by Stanford University — 7 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Stanford University.

Planned enrollment
12th of 25
110 · median 104
Started
2019
with 1 other
No phase
19 of 27
5 open now
Registered
13th of 27
by date

Among the 27 studies in Diabetes Mellitus, Type 2 by Stanford University, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2019, is one of 19 with no phase, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 27 studies in Diabetes Mellitus, Type 2 by Stanford University are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diabetes Mellitus, Type 2 by Stanford University, or all of them as a file.
02

Study summary

This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.

Read the detailed description

Obesity has become an epidemic worldwide. Metabolic/cardiovascular complications of obesity are likely related to the fact that obese individuals tend to be insulin resistant (IR). While insulin- mediated glucose uptake (IMGU) correlates with adipose tissue mass, not all obese individuals are IR, and metabolic and cardiovascular profiles of those who are IR vs insulin sensitive (IS) differ significantly. Why one individual who reaches a BMI of 30 kg/m2 will develop IR and another with similar BMI and activity level remains IS is unclear. Furthermore, while insulin sensitivity improves with weight loss, this response varies as well. Given that fat mass per se does not fully explain the obesity contribution to IMGU, itis likely that differential adipocyte function plays a role. With this study, our purpose is to employ an integrated omics strategy to identify analyte/pathway signatures in blood and adipose tissue that characterize IR versus IS states and expand our biological knowledge of the mechanisms underlying IR.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • PreDiabetes
  • Insulin Resistance
  • Obesity
  • Nonalcoholic Steatohepatitis
  • Nonalcoholic Fatty Liver
  • Diet Modification

Keywords

  • Metabolomics
  • Low Fat Diet
  • Low Carbohydrate Diet
  • Microbiome
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 35-65
  • 25-35 kg/m2
  • Stable body weight
  • Nondiabetic

Exclusion criteria

Exclusion Criteria:

Patients with;

  • diabetes
  • major organ disease
  • history of liposuction or bariatric surgery
  • active eating or psychiatric disorder
  • pregnancy or lactation, heavy alcohol use
  • recent change in weight (over the past 12 weeks)
  • use of weight loss medication, statins, or oral

Clinical screening exclusions;

  • hematocrit \< 33%
  • fasting glucose >/= 126 mg/dL
  • blood pressure >160/100 mmHg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Mediterranean Low Carbohydrate Diet

    Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

    Behavioral: Dietary Intervention Mediterranean Low Carbohydrate Diet

  • Experimental
    Standard Low Carbohydrate Diet

    Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

    Behavioral: Dietary Intervention Standard Low Carbohydrate Diet

  • Experimental
    Low Fat, Healthy Carbohydrate Diet

    Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

    Behavioral: Dietary Intervention Standard Low Fat Diet

Interventions

  • BehavioralDietary Intervention Mediterranean Low Carbohydrate Diet

    Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

  • BehavioralDietary Intervention Standard Low Carbohydrate Diet

    Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

  • BehavioralDietary Intervention Standard Low Fat Diet

    Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline on the 2-stage Steady State Plasma Glucose test

    Compare direct measurement of insulin sensitivity after 4 week diet and weight intervention

    Time frame: Peak weight (4 weeks)

  2. Change from baseline on the radiographic measurement of visceral to subcutaneous (V:S) fat ratio

    Compare measurement of abdominal V:S fat volume via computed tomography (CT) after 4 week diet and weight intervention

    Time frame: Peak weight (4 weeks)

  3. Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition

    Compare measurement of liver fat content via magnetic resonance spectroscopy (MRS) after 4 week diet and weight intervention

    Time frame: Peak weight (4 weeks)

  4. Change from peak weight on the 2-stage Steady State Plasma Glucose test

    Compare direct measurement of insulin sensitivity after 8 week diet and weight intervention

    Time frame: Post-weight loss (8 weeks)

  5. Change from baseline on the radiographic measurement of visceral to subcutaneous (V:S) fat ratio

    Compare measurement of abdominal V:S fat volume via computed tomography (CT) after 8 week diet and weight intervention

    Time frame: Post-weight loss (8 weeks)

  6. Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition

    Compare measurement of liver fat content via magnetic resonance spectroscopy (MRS) after 8 week diet and weight intervention

    Time frame: Post-weight loss (8 weeks)

  7. Measurement of markers of lipid and carbohydrate metabolism and inflammation from adipose mRNA

    Compare adipose tissue transcripts such as known MODY transcription factors, defensin chemokine receptors, and platelet activation factors measured by PCR between participants identified as Insulin sensitive (IS) and Insulin resistant (IR) using the 2-stage Steady State Plasma Glucose test.

    Time frame: Baseline

  8. Quantification of plasma inflammatory cytokine levels in serum samples by Luminex immunoassay

    Compare plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay between participants identified as Insulin Sensitive (IS) and Insulin Resistant (IR) using the 2-stage Steady State Plasma Glucose test.

    Time frame: Baseline

  9. Change from baseline in plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay

    Compare intra-personal levels of plasma inflammatory cytokines as measured by Luminex immunoassay after 4 week diet and weight intervention

    Time frame: Peak Weight (4 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Nov 2026, 93 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 93 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2018
First posted
Dec 21, 2021
StartActual
Jan 31, 2019
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05165706
Responsible party
Tracey McLaughlin (Professor of Medicine, Stanford University) — Principal investigator
First posted
Dec 21, 2021
Start date
Jan 31, 2019
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 4, 2024

Study contacts

Ekrem M Ayhan, BS
Contact
ayhane@stanford.edu
908-619-5381
Dalia Perelman, MS, RD
Contact
daliap@stanford.edu
Tracey McLaughlin, MD
principal investigator · Stanford University, Department of Medicine, Division of Endocrinology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion